Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In the latest close session, Pfizer (PFE) was up +1.67% at $28.55. The stock outperformed the S&P 500, which registered a daily gain of 0.72%. Elsewhere, the Dow saw an upswing of 0.48%, while the ...

A big dividend can’t hide the growth problem at Pfizer (PFE), one of the world’s largest pharmaceutical companies. Pfizer has ...

Pfizer PFE reported fourth-quarter 2025 adjusted earnings per share of 66 cents, which comprehensively beat the Zacks Consensus Estimate of 57 cents per share. Earnings rose 5% year over year.

Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical ...

Pfizer PFE reported a 2% decline in revenue and a 4% increase in adjusted EPS in 2025, and management maintained 2026 revenue guidance for $59.5 billion-$62.5 billion (between flat and a 5% decline) ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer (NYSE: PFE) stock gave up 3.3% through 10:50 a.m. ET Tuesday despite delivering an earnings beat this morning. Analysts forecast the pharmaceuticals giant would earn $0.57 per share on $16.8 ...

Pfizer's per-share profit in 2025 declined as the company incurred significant impairment charges. The company also paid out more in dividends than it generated in free cash flow. Question marks about ...

Pfizer highlighted the performance of a weight-loss drug it acquired in last year's deal to buy Metsera. Pfizer's stock closed 3% lower on Tuesday after investors were disappointed by limited midstage ...

A different side of the healthcare market that has been beaten up last year is the health insurers. The largest in the United ...